Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics-Reference-Cited by-同舟云学术

Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics

Published:2017-06 Issue: Volume:86 Page:221-230
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

de Zafra Christina L.Zuch^ORCID,Sasseville Vito G.,Matsumoto Steven,Freichel Christian,Milton Mark,MacLachlan Timothy K.,Farman Cindy,Raymond Iona,Gupta Swati,Newton Ronald,Atzpodien Elke-Astrid,Thackaberry Evan A.

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference41 articles.

1. The privileged immunity of immune privileged organs: the case of the eye;Benhar;Front. Immunol.,2012

2. Immune response evoked by antigen injection in the rabbit vitreous combined with immunopotentiation;Brinkman;Albr. Graefes Arck Klin Ophthalmol,1981

3. Lucentis™, Ranibizumab Pharmacology/Toxicology Review and Evaluation;CDER (Center for Drug Evaluation and Research),2006

4. Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation;Chapman;Reg. Tox. Pharm.,2013

5. Mechanisms of leukocyte migration across the blood-retina barrier;Crane;Semin. Immunopathol.,2008

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffusion of nanoparticles in heterogeneous hydrogels as vitreous humour in vitro substitutes;Scientific Reports;2024-07-29

2. Diffusion of Nanoparticles in Heterogeneous Hydrogels as Vitreous Humour Substitutes;2024-03-11

3. Intravitreal RTH258 (brolucizumab) demonstrates no effect on pregnancy, parturition, embryofetal or postnatal development in cynomolgus monkeys;Reproductive Toxicology;2023-10

4. International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs;Clinical and Translational Science;2023-02-02

5. Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events;Science Translational Medicine;2023-02